GlassScriptPhysician profile
Gregory J Kent
NPI 1891868006
$4,005.14
in general payments reported to CMS, 2019-2025
21 companies · $665 in 2025
The $665 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $153 · 2021: $1,090 · 2022: $488 · 2023: $193 · 2024: $837 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,280 · Consulting Fee: $416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,279.62 |
| Consulting Fee | $416.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $540.23 | 2021-2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $415.74 | 2019-2024 | Tecnis Simplicity |
| Glaukos Corporation | $378.29 | 2019-2025 | Idosetr |
| Alcon Vision LLC | $348.48 | 2020-2025 | Clareon, Rocklatan, Tryptyr |
| Novartis Pharmaceuticals Corporation | $346.78 | 2019-2023 | |
| Allergan, INC. | $309.45 | 2019-2022 | |
| Abbvie INC. | $304.01 | 2021-2025 | |
| Sight Sciences, INC. | $303.62 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $194.89 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $190.78 | 2019-2025 | Cequa |
| Dompe US, INC. | $158.94 | 2020-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $152.69 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $92.38 | 2023-2025 | Miebo, Vyzulta, Envista Mx60 Iol |
| Beaver-Visitec International, INC. | $53.46 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $44.46 | 2025 | Xdemvy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $40.53 | 2019-2021 | |
| New World Medical,INC. | $37.87 | 2022 | |
| Mallinckrodt Hospital Products INC. | $32.98 | 2025 | Acthar |
| Ani Pharmaceuticals, INC. | $23.52 | 2025 | Iluvien |
| Apellis Pharmaceuticals, INC. | $22.97 | 2024 | Syfovre |
| Shire North American Group INC | $13.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Kent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.